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Syntaphilin controls a mitochondrial rheostat
for proliferation-motility decisions in cancer
M. Cecilia Caino,1,2 Jae Ho Seo,1,2 Yuan Wang,1,2 Dayana B. Rivadeneira,1,2 Dmitry I. Gabrilovich,3 Eui Tae Kim,4
Ashani T. Weeraratna,2 Lucia R. Languino,5 and Dario C. Altieri1,2
Prostate Cancer Discovery and Development Program, 2Tumor Microenvironment and Metastasis Program, and 3Translational Tumor Immunology Program, The Wistar Institute, Philadelphia, Pennsylvania,

1

USA. 4Division of Cancer Pathobiology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 5Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, Pennsylvania, USA.

Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but
the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH),
a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial
SNPH buffers oxidative stress and maintains complex II–dependent bioenergetics, sustaining local tumor growth while
restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of
stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects
and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via
greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the
mitochondrial localization sequence resulted in increased metastatic dissemination in xenograft or syngeneic tumor models
in vivo. Accordingly, tumor cells that acquired the ability to metastasize in vivo constitutively downregulated SNPH and
exhibited higher oxidative stress, reduced cell proliferation, and increased cell motility. Therefore, SNPH is a stress-regulated
mitochondrial switch of the cell proliferation-motility balance in cancer, and its pathway may represent a therapeutic target.

Introduction

Tumors must cope with an unpredictable microenvironment depleted of oxygen and nutrients but saturated in oxidative radicals, toxins,
and immune-inflammatory mediators (1). This requires a process of
adaptation, or “plasticity” (2), that improves tumor fitness via genetic and nongenetic changes (3, 4), buffers stress signals (5), and reprograms metabolism for tailored bioenergetics needs (6).
A key decision in tumor adaptation is how best to allocate
limited resources in the microenvironment (1) to either support
cell proliferation, and therefore local tumor growth; or, conversely, stimulate cell motility (7), thus enabling the dissemination
of transformed cells to distant organs, or metastasis (8). Both
responses are intensely energy-intensive, and it has been speculated that tumors can undergo dynamic cycles of each process,
but not both at the same time in a mechanism called cell proliferation-motility dichotomy (9), or phenotype-switching (10).
Although this process may dictate metastatic competence and
ultimately influence disease outcome, its mechanistic underpinnings (9) have remained elusive (11), with only a handful of regulators of cell cycle transitions (12), transcriptional (13) and translational (14) programs, and membrane dynamics of cell motility
(15) potentially implicated in phenotype switching (16).
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In this context, a role for metabolic reprogramming in phenotype switching has not been widely investigated. We know that
most tumors adopt a mostly glycolytic metabolism, the so-called
Warburg effect (6), but recent evidence has reinforced a central
role of mitochondrial biology as a driver of cancer traits (17, 18),
in particular metastatic competence (19), even under microenvironment stress (20). Several mechanisms have been implicated in
this process, including modulation of oxidative stress (21); cycles
of organelle fusion and fission, i.e. dynamics (22); and horizontal transfer of respiration-competent mitochondria from stromal
cells (23, 24). Recently, an additional mechanism of active mitochondrial trafficking to the cortical cytoskeleton has been linked
to greater tumor cell invasion and metastasis (25, 26), potentially by providing a concentrated, “regional” energy source to fuel
membrane dynamics of chemotaxis and tumor cell movements.
Unexpectedly, a key regulator of this pathway was identified as
syntaphilin (SNPH), a cytoskeletal protein known in neurons
for arresting mitochondrial movement at sites of high energy
demands (27, 28). Instead, SNPH was found to be expressed in
cancer, but downregulated in advanced disease settings, blocking
mitochondrial trafficking to the cortical cytoskeleton and suppressing cell motility and invasion (29).
In this study, we explored the complexity of the SNPH pathway
(29) as a potential regulator of proliferation-motility decisions in
tumors (7). We identified an alternatively spliced isoform of SNPH
that localizes to mitochondria of tumor cells and orchestrates bioenergetics, buffering of ROS, and differential modulation of tumor
cell proliferation versus cell invasion and dissemination, in vivo.
jci.org   Volume 127   Number 10   October 2017
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Figure 1. SNPH isoforms. (A) Schematic diagram of the human SNPH locus (based on the Vertebrate Genome Annotation [Vega] repository; http://
vega.archive.ensembl.org/index.html). The position and sequences of intron-exon boundaries, long (L) or short (S) SNPH transcripts, and TaqMan gene
expression assays utilized for mRNA amplification of the two SNPH isoforms are indicated. (B) Schematic diagram of L-SNPH or S-SNPH protein isoforms.
Pro, proline. (C and D) The indicated normal human tissues (C), normal diploid (MRC5) cells, or tumor cell types (D) were analyzed for L-SNPH or S-SNPH
mRNA copy number, and normalized to 1,000 molecules of β-actin. Mean ± SEM (n = 3 per tissue or cell line examined). (E) PC3 cells were fractionated in
cytosol (Cyto) or mitochondrial (Mito) extracts and analyzed by Western blotting. TCE, total cell extracts. (F) MCF-7 cells devoid of endogenous SNPH as in
D were transfected with SNPH cDNA and analyzed by fluorescence microscopy. Merge image includes the F-actin channel (cyan). Scale bar: 5 μm. (G) PC3
cells were fractionated in sub-mitochondrial extracts containing outer membrane (OM), inter-membrane space (IMS), inner membrane (IM), or matrix (M)
and analyzed by Western blotting. The expression of SDHB, cytochrome c (Cyto c), or ClpP was used as a markers for each fraction. MTE, unfractionated
mitochondrial extracts.

Results

Identification of alternatively spliced SNPH isoforms. A genome-wide
shRNA screen recently identified SNPH as a regulator of mitochondrial trafficking in tumors and potential metastasis suppressor (29). Here, inspection of the human SNPH locus indicated the
presence of at least two SNPH transcripts, potentially originated by
alternative splicing of the 5′ end of the SNPH gene (Figure 1A). This
process generated a previously unrecognized short SNPH isoform
(S-SNPH) of 494 amino acids containing a mitochondrial localization sequence (MLS) embedded in a new amino-terminal region
(Figure 1, A and B). In contrast, a long SNPH isoform (L-SNPH) of
538 amino acids corresponded to previously described “neuronal”
SNPH (27, 28), containing an extra 44-amino-acid NH2-proline–rich
region and no MLS (Figure 1, A and B). Downstream of the first 44
residues, the two SNPH proteins were identical (Figure 1, A and B).
We next used gene expression assays that individually detect
L-SNPH or S-SNPH (Figure 1A) to map the distribution and absolute abundance of the two isoforms in human tissues and cell
3756
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lines. L-SNPH was expressed in normal brain but mostly undetectable in all other tissues examined, including breast, colon, heart,
kidney, liver, and lung, and present at a low level in the prostate
(Figure 1C). Unexpectedly, S-SNPH was expressed at levels comparable to or higher than those of L-SNPH in the brain, and was
present in other tissues, including heart, kidney, lung, and prostate (Figure 1C). S-SNPH was also the dominant isoform in normal
and tumor cell lines, whereas L-SNPH was present at a low level
or undetectable (Figure 1D). Similar results were obtained with
analysis of public databases, with broad expression of SNPH in all
human tumors examined, albeit at different levels (Supplemental
Figure 1A; supplemental material available online with this article;
https://doi.org/10.1172/JCI93172DS1), as well as human cell lines
representative of disparate tumor types (Supplemental Figure 1B).
Consistent with a predicted MLS (Figure 1B), S-SNPH (hereafter referred to as SNPH) was detected by Western blotting in
both cytosol and mitochondria of prostate adenocarcinoma PC3
cells (Figure 1E). Similarly, SNPH transfected in breast adeno-
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Figure 2. SNPH regulation of mitochondrial bioenergetics. (A and B) PC3 cells stably transduced with control pLKO or shRNA-SNPH (clone 0 or 5) were
analyzed for OCR (A) or ATP production (B). Data are expressed as mean ± SD of replicates of a representative experiment (n = 3). ***P < 0.0001, by
2-tailed Student’s t test (A). ***P < 0.001 by ANOVA and Bonferroni’s post-test (B). (C and D) PC3 cells transfected with control siRNA (Ctrl) or siRNA-
SNPH were transduced with control adenovirus (Ad-LacZ) or SNPH-directed adenovirus (Ad-SNPH), and analyzed for OCR (C) or ATP production (D). Data
are expressed as mean ± SD of replicates of a representative experiment (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (E and F) PC3 cells
transduced with pLKO or shRNA-SNPH were analyzed for oxidative phosphorylation complex II (C.II) activity (E) and normalized to citrate synthase activity
(F). Gray tracing, blank reaction. Data are expressed as mean ± SD of replicates of a representative experiment (n = 3). **P < 0.01 by ANOVA and Bonferroni’s post-test. (G and H) The experimental conditions were as in E and F, except that transduced PC3 cells were analyzed for oxidative phosphorylation
complex I (C.I) activity (G) and normalized to citrate synthase activity (H). Gray tracing, blank reaction. Data are expressed as mean ± SD of replicates of a
representative experiment (n = 3). NS, not significant (P > 0.05) by ANOVA and Bonferroni’s post-test. (I) PC3 cells transduced with pLKO or shRNA-SNPH
were treated with CHX, and aliquots of cell extracts harvested at the indicated time intervals after release (h) were analyzed by Western blotting. (J and
K) Protein bands from the experiment in I were quantified by densitometric scanning after CHX release. Changes in SDHA (J) or SDHB (K) protein bands in
pLKO or shRNA-SNPH are shown. Data are expressed as mean ± SD (n = 4). The statistical analyses are as follows: SDHA (J), 2 hours, P = 0.05; 4 hours,
P < 0.0001; 6 hours, P = 0.0001; 8 hours, P = 0.0001; 10 hours, P < 0.0001; SDHB (K), 2 hours, P = 0.14; 4 hours, P = 0.0007; 6 hours,
P < 0.0001; 8 hours, P < 0.0001; 10 hours, P < 0.0001, by 2-tailed Student’s t test.

carcinoma MCF-7 cells, which are devoid of endogenous SNPH
(Figure 1D; see complete unedited blots in the supplemental
material.), localized to mitochondria, by fluorescence microscopy (Figure 1F). In terms of submitochondrial distribution, endogenous SNPH localized to both the inner and outer mitochondrial
membranes of tumor cells, whereas matrix and inter-membrane
space were unreactive (Figure 1G).
Mitochondrial SNPH regulates bioenergetics. To probe the function
of SNPH in mitochondria, we next used multiple independent siRNA
sequences that silence the expression of SNPH mRNA (Supplemental Figure 1C) and protein (Supplemental Figure 1D) in tumor and
normal cell types. As an additional, alternative approach, we generated two independent clones of PC3 cells with stable knockdown of
SNPH by short hairpin RNA (shRNA) (Supplemental Figure 1E). As
cellular models for the targeting experiments, we focused on PC3
and glioblastoma LN229 cells, representative of neuroendocrine and
CNS origin, respectively, with high endogenous SNPH expression
(Figure 1D). SNPH siRNA silencing did not affect total mitochondrial mass, compared with control transfectants (Supplemental Figure

2A). Conversely, shRNA-mediated loss of SNPH decreased oxygen
consumption rates (OCR), a marker of oxidative metabolism (Figure
2A), and reduced overall adenosine triphosphate (ATP) production in
PC3 cells (Figure 2B). Glycolytic metabolism was also affected, with
a modest, but significant, decrease in glucose consumption (Supplemental Figure 2B) and lactate production (Supplemental Figure 2C)
after shRNA-SNPH knockdown. To validate these results, we next
carried out reconstitution experiments in which SNPH-depleted PC3
cells were transduced with adenovirus expressing SNPH (Ad-SNPH)
(Supplemental Figure 2, D and E). Under these conditions, reexpression of SNPH restored OCR (Figure 2C) and ATP production (Figure 2D), whereas Ad-LacZ (Supplemental Figure 2, D and E) had no
effect (Figure 2, C and D).
To further characterize the role of SNPH in mitochondrial
metabolism, we next looked at the activity of individual oxidative
phosphorylation complexes. Stable depletion of SNPH in PC3 cells
reduced the activity of mitochondrial complex II (Figure 2, E and
F), but not complex I (Figure 2, G and H), compared with control
transfectants. This was associated with decreased expression of
jci.org   Volume 127   Number 10   October 2017
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Figure 3. Effect of SNPH on mitochondrial oxidative stress. (A) LN229 cells expressing control siRNA (Ctrl) or siRNA-SNPH were transfected with cDNA
encoding antioxidant SOD2 or Prx3 and analyzed for total ROS production by fluorescence microscopy. Data are expressed as mean ± SD of single-cell
determinations (Ctrl, n = 109; SNPH, n = 75; SOD2, n = 74; and Prx3, n = 55). **P < 0.01 by ANOVA and Bonferroni’s post-test. CellROX, ROS sensor. (B) PC3
cells transduced with pLKO or shRNA-SNPH (clones 0 and 5) were analyzed for mitochondrial superoxide production (mitoSOX) by fluorescence micro
scopy. Data are expressed as mean ± SD of single cell determinations (pLKO, n = 202; SNPH #0, n = 296; SNPH #5, n = 297). ***P < 0.001 by ANOVA and
Bonferroni’s post-test. FU, fluorescence units. (C) PC3 shRNA-SNPH #0 cells were analyzed for NAD+/NADH ratio. Data are expressed as mean ± SD of
replicates of a representative experiment (n = 3). **P = 0.001, by 2-tailed Student’s t test. (D–F) PC3 cells were treated with the indicated increasing concentrations of the oxidative stimuli DMNQ (D), H2O2 (E), and paraquat (PQ, F) and analyzed by Western blotting. Bottom panels (E and F): Densitometric
quantification of SDHA, SDHB, or Prx-SO3 protein bands. Data are expressed as mean ± SD (n = 3). *P < 0.05; **P < 0.01; by ANOVA and Bonferroni’s posttest. (G) PC3 shRNA-SNPH #0 cells were treated with the mitochondrial superoxide scavenger MT and incubated with CHX, and cell extracts harvested
at the indicated time intervals after release (h) were analyzed by Western blotting. (H) Densitometric quantification of SDHA, SDHB, or COX-IV proteins
bands from the experiment in G. Data are expressed as mean ± SD (n = 4). The statistical analyses are as follows: SDHA, 2 hours, NS; 4 hours, P = 0.001; 6
hours, NS; 8 hours, NS; 10 hours, P = 0.033; SDHB, NS for all time points; COX-IV, NS for all time points by 2-tailed Student’s t test.

the complex II subunits succinate dehydrogenase A (SDHA) and
B (SDHB) (Supplemental Figure 2F), whereas SDHC or complex
III or complex V subunits were not affected (Supplemental Figure
2F and Supplemental Figure 1E). Consistent with these findings,
shRNA-SNPH knockdown resulted in accelerated degradation
of SDHA and SDHB (Figure 2I), and significantly shortened the
half-life of both proteins, as quantified in cycloheximide (CHX)
block experiments (Figure 2, J and K). Other subunits of oxidative phosphorylation complexes, including ATP5A (complex V)
and UQCRC2 (complex III), were not affected (Figure 2I), and the
half-life of COX-IV (complex IV) was unchanged with or without
SNPH knockdown (Supplemental Figure 2G).
Mitochondrial SNPH regulation of oxidative stress. Consistent
with defective mitochondrial bioenergetics, shRNA-SNPH knockdown in PC3 cells resulted in increased production of total ROS
(Figure 3A). Specifically, loss of SNPH was associated with heightened generation of mitochondria-derived superoxide, compared
with control transfectants (Figure 3B). Known cellular markers of
3758
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oxidative stress, including hyperoxidation of peroxiredoxin 3 (Prx3)
(Supplemental Figure 3B), and increased NAD+/NADH ratio (Figure 3C) were also elevated in these settings. In rescue experiments,
transfection of shRNA-SNPH–depleted cells with cDNA encoding
the antioxidant SOD2 or Prx3 (Supplemental Figure 3B) reversed
the increase in total cellular ROS (Figure 3A), as well as mitochondrial superoxide production (Supplemental Figure 3C).
Based on these observations, we next asked whether oxidative
damage affected the stability and/or function of mitochondrial
oxidative phosphorylation complex subunits. Consistent with this
possibility, treatment of PC3 cells with the oxidative stress stimulus
2,3-dimethoxy-1,4-naphthoquinone (DMNQ) resulted in a concentration-dependent decrease in SDHA and SDHB expression (Figure
3D and Supplemental Figure 3D). Consistent with oxidative damage, this was associated with Prx3 hyperoxidation and potent induction of the oxidative stress–regulated, cytoprotective transcription
factor Nrf2 (30) in treated cells (Figure 3D and Supplemental Figure 3D). Similar results were obtained after exposure of PC3 cells
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Figure 4. SNPH regulation of mitochondrial oxidative stress controls tumor cell motility. (A) LN229 cells were transfected with vector or Flag-SNPH cDNA
and analyzed for subcellular mitochondrial localization by confocal fluorescence microscopy. Three-dimensional isosurface renderings of representative cells
are shown. (B) LN229 cells transfected with control siRNA or siRNA-SNPH were treated with vehicle or MT (200 μM) and analyzed by fluorescence microscopy.
Masks are superimposed to the mitochondrial fluorescence channel (MTC02) to indicate the cell border (cyan lines, based on the actin channel) and the cortical
region (area between the cyan and magenta lines). Arrowheads, cortical mitochondria. Scale bar: 10 μm. (C–E) LN229 cells transfected with siRNA-SNPH were
transfected with vector, SOD2, or Prx3 cDNA and analyzed for cell motility in a 2D chemotaxis chamber (C), with quantification of speed of cell migration (D)
and distance traveled by individual cells (E). Each tracing in C and symbol in E corresponds to an individual cell. Data are expressed as mean ± SEM (n = 91–112).
***P < 0.0001, by ANOVA and Bonferroni’s post-test. The cutoff velocities for each condition in 2D chemotaxis experiments (C) are indicated.

to hydrogen peroxide (Figure 3E) or paraquat (Figure 3F), a redox
cycler that stimulates superoxide production, resulting in concentration-dependent loss of SDHB and, to a lesser extent, SDHA
expression (Figure 3, E and F). Conversely, selective scavenging
of mitochondrial superoxide with MitoTempo (MT) inhibited
the increase in mitochondrial ROS induced by SNPH knockdown
(Supplemental Figure 3F), and restored SDHA and SDHB levels in
these settings (Figure 3G). Accordingly, MT treatment normalized
the half-life of both complex II subunits, SDHA and SDHB, in CHX
block experiments (Figure 3, G and H), whereas the half-life of
COX-IV was unchanged with or without MT (Figure 3H).
SNPH regulation of oxidative stress controls mitochondrial trafficking and tumor cell motility. Next, we asked whether SNPH regulation of mitochondrial oxidative stress was important for tumor
behavior. For these experiments, we used the model of LN229
glioblastoma cells, recently utilized to characterize the SNPH
pathway in tumors (29), as well as prostate adenocarcinoma C4-2B
cells, which have undetectable levels of endogenous SNPH (Figure 1D). Using these cellular models, forced expression of SNPH
was sufficient to suppress mitochondrial trafficking to the cortical
cytoskeleton (Figure 4A and Supplemental Figure 4A), which fuels
membrane dynamics of chemotaxis and cell invasion (29).
Mechanistically, treatment of SNPH-depleted LN229 cells with
MT, alone or in combination with the ROS scavenger N-acetyl-cysteine (NAC) suppressed mitochondrial trafficking to the cortical cytoskeleton (Figure 4B and Supplemental Figure 4, B and C). In turn,
MT treatment, with or without NAC, was sufficient to suppress the

increased chemotaxis associated with SNPH depletion (Supplemental Figure 4C), reducing the speed of cell movements (Supplemental
Figure 4D) and the distance traveled by individual cells (Supplemental Figure 4E). Similar results were obtained with an independent experimental approach, where transfection of SNPH-depleted LN229 cells with antioxidant SOD2 or Prx3 also reversed the
increased chemotaxis induced by SNPH loss (Figure 4C), with comparable inhibition of the speed of cell migration (Figure 4D) and distance traveled per cell (Figure 4E) to the levels of control cultures.
Mitochondrial SNPH differentially regulates tumor cell proliferation. In addition to increased cell motility (Figure 4C and Supplemental Figure 4D), SNPH depletion blocked tumor cell proliferation
(Figure 5A, top) without loss of cell viability (Figure 5A, bottom).
Importantly, tumor cells lacking endogenous SNPH, including
C4-2B or breast adenocarcinoma MCF-7 cells (Supplemental Figure 5A), were not affected (red boxes in Figure 5A, top). Consistent
with these data, loss of SNPH also suppressed colony formation in
semisolid medium (Figure 5, B and C). In reciprocal experiments,
forced expression of SNPH was sufficient to increase tumor cell
proliferation, compared with control transfection (Figure 5D). The
requirement(s) of SNPH regulation of tumor cell proliferation was
next investigated. SNPH depletion did not appreciably affect BrdU
incorporation (Supplemental Figure 5B), a measure of S-phase,
but significantly increased the percentage of cells with G2/M DNA
content (Supplemental Figure 5C), suggestive of mitotic arrest.
Consistent with this possibility, SNPH depletion was associated
with increased levels of mitotic cyclin B1, whereas the expression
jci.org   Volume 127   Number 10   October 2017
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Figure 5. Mitochondrial SNPH supports tumor cell proliferation. (A) The indicated tumor cells transfected with control siRNA (Ctrl) or siRNA-SNPH were
analyzed by direct cell counting (top) or cell viability by trypan blue exclusion (bottom) after 72 hours. The same number of cells were seeded at time 0.
Data are expressed as mean ± SEM (n = 4). Red boxes indicate two cell types (C4-2B and MCF-7) with low to undetectable levels of endogenous SNPH. The
statistical analyses per each cell type are as follows: BPH1, P = 0.03; A549, P = 0.004; H1299, NS; C4-2B, NS; DU145, P = 0.03; PC3, P = 0.002; LN229, P =
0.002; U251, P < 0.0001; U87, P = 0.03; MCF-7, NS; MDA-231, P = 0.01; Hs578T, P = 0.02 by 2-tailed Student’s t test. (B and C) PC3 cells transduced with pLKO
or shRNA-SNPH (clones 0 and 5) were analyzed in a colony formation assay, and crystal violet–stained colonies (B) were counted after 10 days (C). Data are
expressed as mean ± SEM (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (D) The indicated tumor cell types were transfected with vector or
SNPH cDNA and analyzed by direct cell counting after 72 hours. Data are expressed as mean ± SD (n = 3). ***P < 0.0001, by 2-tailed Student’s t test. (E) PC3
cells transduced with pLKO or shRNA-SNPH were transfected with SOD2 cDNA and analyzed by direct cell counting. Data are expressed as mean ± SD (n = 3).
*P < 0.01, by ANOVA and Bonferroni’s post test. (F) PC3 cells transduced with shRNA-SNPH were reconstituted with vector or SOD2 cDNA and analyzed by
propidium iodide staining and flow cytometry. The cellular fractions in the indicated cell cycle phases are indicated. Data are expressed as mean ± SD (n = 3).
**P = 0.01 by 2-tailed Student’s t test.

of cyclin A or cyclin D1 was unchanged (Supplemental Figure 5D).
Mechanistically, transfection of SNPH-depleted cells with antioxidant SOD2 cDNA restored tumor cell proliferation (Figure 5E) and
reversed the cell cycle arrest at G2/M (Figure 5F), compared with
control transfection.
Mitochondrial SNPH modulates cell proliferation–cell motility
decisions in cancer. Next, we asked whether the mitochondrial
localization of this SNPH isoform was required for tumor functions. Reconstitution of shRNA-SNPH–silenced PC3 cells with
full-length (FL) SNPH (Supplemental Figure 6A) reversed the
bioenergetics defects in oxygen consumption (Figure 6A) and
ATP production (Figure 6B) associated with SNPH depletion.
Conversely, reconstitution of these cells with a SNPH mutant
lacking the MLS (Δ-MLS) was ineffective (Figure 6, A and B,
and Supplemental Figure 6A). In these studies, FL SNPH and
Δ-MLS SNPH were expressed at comparable levels in reconstituted PC3 cells (Supplemental Figure 6A). Next, we examined
the requirement of mitochondrial localization in SNPH regulation of mitochondrial movement and cell motility-proliferation.
Consistent with the data above, forced expression of FL SNPH
in C4-2B cells (Supplemental Figure 6B) inhibited mitochondrial
trafficking to the cortical cytoskeleton (Figure 6C) and promoted
increased cell proliferation (Figure 6D), compared with control
transfection. Conversely, expression of Δ-MLS SNPH in C4-2B
cells (Supplemental Figure 6B) was considerably less effective, partially reducing mitochondrial trafficking (Figure 6C)
and modestly increasing cell proliferation (Figure 6D). Similar
results were obtained in LN229 cells, where FL SNPH inhibited
mitochondrial trafficking (Supplemental Figure 6C) and promoted cell proliferation (Supplemental Figure 6D), whereas Δ-MLS
3760
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SNPH had a limited effect (Supplemental Figure 6, C and D).
Finally, reconstitution of shRNA-SNPH–depleted PC3 cells with
FL SNPH abolished the increase in tumor cell invasion induced
by SNPH loss, whereas Δ-MLS SNPH had no effect (Figure 6E
and Supplemental Figure 6E).
Based on these observations, we next asked whether the
localization of SNPH to mitochondria was required to modulate tumor cell dissemination in vivo. For these experiments, we
utilized the mCherry-labeled Yumm1.7 cell line, derived from a
genetically engineered mouse model of invasive melanoma carrying the genotype BrafV600E; Cdkn2a–/–;Pten–/– (31) and utilized
in recent studies (32). For these experiments, Yumm1.7 cells
expressing negligible levels of endogenous SNPH (Supplemental Figure 6F) were stably transfected with vector or SNPH variants and first analyzed for cell motility/proliferation responses
in culture. Transfection of FL SNPH suppressed Yumm1.7 cell
invasion across Matrigel, compared with vector control transfection (Supplemental Figure 6G) and in agreement with the data
above. In contrast, expression of Δ-MLS SNPH had no effect in
Yumm1.7 cells (Supplemental Figure 6G). In these experiments,
expression of FL SNPH or Δ-MLS SNPH did not significantly
modulate proliferation of Yumm1.7 cells (Supplemental Figure
6H). When reconstituted subcutaneously in syngeneic C57BL/6
mice, Yumm1.7 cells expressing vector disseminated to the lung,
as quantified by immunocytochemistry of mCherry reactivity
(Figure 6, F and G), and in agreement with recent observations
(32). Under these conditions, expression of FL SNPH abolished
metastatic seeding of Yumm1.7 cells to the lungs, whereas transfection of Δ-MLS SNPH was associated with increased tumor cell
dissemination in vivo (Figure 6, F and G).
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Figure 6. Mitochondrial SNPH regulation of metastasis. (A and B) siRNA-SNPH PC3 cells were reconstituted with vector (pCMV), FL SNPH, or an SNPH
mutant deleted in the MLS (Δ-MLS), and analyzed for OCR (A) or ATP production (B). Data are mean ± SD (n = 3). **P < 0.01; ***P < 0.001 by ANOVA and
Bonferroni’s post-test. (C and D) C4-2B cells were transfected with pCMV6, FL SNPH, or Δ-MLS SNPH and analyzed for mitochondrial trafficking to the cortical cytoskeleton (C) or direct cell counting (D). For C, data are mean ± SEM (vector, n = 89; FL SNPH, n = 96; Δ-MLS SNPH, n = 87). **P < 0.01; ***P < 0.001
by ANOVA and Bonferroni’s post-test. For D, data are mean ± SD (n = 6). (E) shRNA-SNPH PC3 cells were reconstituted with pCMV6, FL SNPH, or Δ-MLS
SNPH and analyzed for Matrigel invasion. Data are mean ± SEM (n = 3). ***P < 0.001, by ANOVA and Bonferroni’s post-test. (F) Yumm1.7 cells expressing
mCherry and stably transfected with pCMV6, FL SNPH, or Δ-MLS SNPH were injected subcutaneously into syngeneic C57BL/6 mice, and mCherry-positive
cells (insets) disseminated to the lungs were detected by immunocytochemistry. Scale bar: 50 μm. (G) Quantification of mCherry-positive Yumm1.7 cells
transfected as in F in lungs of reconstituted animals. Each symbol corresponds to the mean number of disseminated cells per lung of an individual animal.
DTC, disseminated tumor cells. *P < 0.05; ***P < 0.001, by ANOVA and Bonferroni’s post-test.

Reciprocal regulation of tumor growth and metastasis by SNPH.
We next carried out a reciprocal experiment in vivo and analyzed
the xenograft growth of PC3 cells stably transduced with two independent shRNA-SNPHs in immunocompromised mice. In these
experiments, stable depletion of SNPH suppressed the growth
of superficial PC3 xenograft tumors, compared with pLKO transfection (Figure 7A). To further investigate the role of this pathway
in metastasis, we isolated pLKO-transfected cells that had spontaneously metastasized to the lung or liver of engrafted animals.
These lung or liver metastatic cell lines showed constitutive downregulation of SNPH (Figure 7B) and markers of oxidative stress,
including greater mitochondrial superoxide production (Figure
7C) and Prx hyperoxidation and reduced SOD2 levels (Figure 7D).
In line with these findings, analysis of public databases revealed
that metastatic breast cancer (Supplemental Figure 7A) or metastatic prostate cancer (Supplemental Figure 7B) had reduced levels
of SNPH compared with the corresponding primary tumor. Phenocopying the effect of SNPH silencing, loss of endogenous SNPH
in metastatic tumor cells was associated with decreased expression of the complex II subunits SDHA and SDHB (Figure 7D and
Supplemental Figure 7C), diminished complex II activity (Figure
7E and Supplemental Figure 7D), and lower OCR (Supplemental
Figure 7E), compared with parental, pLKO transfection.
When analyzed for changes in the cell proliferation-motility balance, lung or liver metastatic cells showed reduced colony formation
(Figure 7, F and G) but increased 2D chemotaxis (Figure 7H), characterized by greater speed of cell migration (Figure 7I) and longer distance traveled by individual cells (Supplemental Figure 7F). Finally,
these metastatic cells expressed markers of epithelial-mesenchymal
transition (EMT), including β-catenin, Slug, and vimentin (Figure

7J), whereas ZO1 modulation was observed in lung but not liver metastatic cells, and claudin 1 expression was unchanged (Figure 7J).
Stress-regulated exploitation of the SNPH pathway in cancer.
Next, we asked whether stress conditions of the tumor microenvironment affected SNPH levels in tumors. Exposure of PC3 cells to
hypoxia (1% O2 for 24 hours) acutely downregulated SNPH levels
(Figure 8A) as early as 3 hours after treatment (Supplemental Figure 8A), and was associated with Prx hyperoxidation and HIF1α
stabilization (Figure 8A). Similar findings were observed in cases
of clear cell renal cell carcinoma in vivo, where HIF1α stabilization
due to mutations or deletions in its negative regulator von Hippel–Lindau (VHL) (33) (Figure 8B) or decreased VHL copy number
(Supplemental Figure 8B) correlated with reduced levels of SNPH.
Functionally, loss of SNPH in hypoxic cells was associated with
increased mitochondrial trafficking to the cortical cytoskeleton
(Figure 8, C and D) and greater tumor cell motility, as determined
in a wound closure assay (Supplemental Figure 8, C and D). Oxidative stress generated by DMNQ treatment also lowered SNPH
protein (Figure 8E) and mRNA (Figure 8F) expression in PC3 cells.
Finally, we asked whether the SNPH pathway was selectively
exploited in cancer, compared with normal cells. Silencing of SNPH in
primary human HFFs or normal prostate epithelial RWPE1 cells had
marginal effects on cellular bioenergetics, with a modest decrease in
OCR (Figure 8G) and ATP production (Figure 8H). Similarly, SNPH
silencing in HFF cultures did not generate oxidative stress, with no
Prx3 hyperoxidation observed in these settings (Supplemental Figure 8E). Finally, depletion of SNPH in either HFFs or RWPE1 cells
did not affect 2D chemotaxis (Figure 8I), with no changes observed
in the speed of cell migration (Figure 8J) or distance traveled per cell
(Figure 8K), compared with control transfectants.
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Figure 7. SNPH regulation of cell proliferation-motility in vivo. (A) PC3 cells transduced with pLKO or shRNA-SNPH (clones 0 and 5) were injected
subcutaneously in immunocompromised mice (5 mice per group; 2 tumors/mouse), and tumor volume was quantified with a caliper at the indicated
time intervals. Each symbol corresponds to an individual tumor. On day 20, pLKO vs. SNPH #0, P < 0.001; pLKO vs. SNPH #5, P < 0.05, by ANOVA and
Bonferroni’s post-test. (B) pLKO-transduced PC3 cells or pLKO-transduced PC3 cells isolated from a liver or lung metastatic site (Met) from the experiment
in A were analyzed for SNPH mRNA levels by qPCR. Data are expressed as mean ± SD (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (C and
D) The metastatic cell lines in B were analyzed for mitochondrial superoxide production by mitoSOX reactivity and fluorescence microscopy (C) or Western
blotting (D). Data in C are expressed as mean ± SEM of single-cell determinations (n = 76–200). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (E)
The indicated metastatic cell lines were analyzed for mitochondrial oxidative phosphorylation complex II (C.II) activity at the indicated time intervals. (F
and G) The indicated metastatic cell lines were analyzed in a colony formation assay (F), and crystal violet–stained colonies were quantified after 10 days
(G). Data are expressed as mean ± SD (n = 3). **P < 0.01; ***P < 0.001 by ANOVA and Bonferroni’s post-test. (H and I) The indicated metastatic cell lines
were analyzed for cell motility in a 2D chemotaxis chamber (H) with quantification of speed of cell migration (I). Data are expressed as mean ± SEM (n =
104–106). ***P < 0.0001, by ANOVA and Bonferroni’s post-test. (J) The indicated metastatic cell lines were analyzed by Western blotting.

Discussion

In this study, we have identified an alternatively spliced isoform
of SNPH (27, 28) that localizes to mitochondria and functions as a
stress-regulated switch for proliferation-motility decisions in cancer. High levels of SNPH maintain efficient, “non-leaky” mitochondrial bioenergetics, which sustains tumor cell proliferation
while suppressing cell motility (Figure 9). Reciprocally, downregulation of SNPH due to oxidative or hypoxic stress impairs mitochondrial metabolism, shuts off cell proliferation and stimulates
greater tumor cell motility and invasion (Figure 9). A critical signaling regulator of this response was mitochondria-produced
superoxide, which promoted oxidative degradation of the complex II subunits SDHA and SDHB, cell cycle arrest at G2/M, and
heightened mitochondrial trafficking to the cortical cytoskeleton
to fuel membrane dynamics of cell motility (Figure 9). Altogether,
this pathway functioned as a major switch to regulate the metastatic propensity in vivo, as depletion of SNPH or expression of a
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SNPH mutant lacking the MLS dramatically increased metastatic
dissemination in syngeneic as well as xenograft tumor models in
vivo. Accordingly, tumor cell lines established from lung or liver
metastatic sites in vivo exhibited lower levels of SNPH compared
with their primary sites, higher oxidative stress, reduced cell proliferation, and heightened cell motility.
Previously considered “neuron-specific” (27), SNPH has been
known as a negative regulator of mitochondrial trafficking, tethering mitochondria to cytoskeletal microtubules and halting their
movements at axonal regions with high energy demands (28).
Unexpectedly, a similar pathway was recently uncovered in cancer
(29), where SNPH prevented the repositioning of mitochondria to
the cortical cytoskeleton, a process that fuels chemotaxis and cell
invasion (25, 26), thus suppressing tumor cell movements (29).
Here, we uncovered a mechanistic underpinning of the SNPH
pathway in cancer, centered on the expression of a previously
unrecognized, alternatively spliced SNPH isoform, characterized
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Figure 8. Hypoxic and oxidative stress regulation of SNPH. (A) PC3 cells were exposed to normoxia (N) or hypoxia (H; 1% O2 for 24 hours) and analyzed by
Western blotting. (B) Cases of clear cell renal cell carcinoma in the TCGA database were stratified for SNPH mRNA expression and VHL mutational status.
Mut, mutations; Trunc, truncated; del, deletions. Each symbol corresponds to an individual tumor. **P < 0.01; ***P < 0.001 by ANOVA and Bonferroni’s
post-test. (C and D) LN229 cells exposed to normoxia or hypoxia as in A were analyzed for mitochondrial trafficking to the cortical cytoskeleton by fluorescence microscopy (C), and cortical mitochondria (mito) were quantified (D). Each symbol corresponds to an individual cell. ***P < 0.0001, by 2-tailed
Student’s t test. The representative images displayed in C are brightness- and contrast-enhanced to highlight cortical mitochondria. Quantification was
done in unsaturated images. (E and F) PC3 cells were treated with the indicated concentrations of DMNQ and analyzed by Western blotting (E) or qPCR
amplification of SNPH mRNA (F). Data are expressed as mean ± SD (n = 3). ***P < 0.001, by ANOVA and Bonferroni’s post-test. (G and H) Normal diploid
HFFs or normal human prostate epithelial cells (RWPE1) were transfected with control siRNA or siRNA-SNPH and analyzed for OCR (G) or ATP production
(H). Data are mean ± SD (HFFs, n = 3; RWPE1, n = 12). *P = 0.001 to P < 0.0001; NS, not significant, by 2-tailed Student’s t test. (I) HFFs (top) or RWPE1
cells (bottom) transfected as in G were analyzed for cell motility in a 2D chemotaxis chamber. Each trace corresponds to the movements of an individual
cell. (J and K) HFFs or RWPE1 cells transfected as in G were analyzed by 2D chemotaxis, and speed of cell migration (J) and distance traveled by individual
cells (G) were quantified. Data are expressed as mean ± SD (HFFs, n = 35–42; RWPE1 cells, n = 50–52). NS, 2-tailed Student’s t test.

by a unique mitochondrial localization. At variance with a canonical, long SNPH isoform, which corresponds to previously described
“neuronal” SNPH (27), the new, short SNPH isoform was broadly expressed, albeit at wide-ranging levels, in both neuronal and
non-neuronal tissues, including primary human tissues and tumor
cell lines. A detailed molecular understanding of how the SNPH
gene is differentially processed, including the potential generation
of additional isoform(s) from this locus, remains to be elucidated.
However, it is intriguing that analysis of public databases points to
a potential role of stress-regulated transcriptional mechanisms in
SNPH gene expression, in keeping with the stress-regulated modulation of SNPH levels observed here in tumor cells.
Consistent with its predicted mitochondrial localization, the
new, short SNPH isoform accumulated in mitochondria of tumor
cells, sorting to both the inner and outer organelle membranes. It
seems plausible that the putative transmembrane (TM) domain
embedded in the COOH-terminus of SNPH (27) provides membrane insertion at both mitochondrial locations, and, consistent
with this possibility, deletion of the TM domain disrupted mitochondrial tethering to cytoskeletal microtubules (27) and impaired
mitochondrial support of tumor cell proliferation (our unpublished

observations). Together, these data suggest the possibility of a differential spatial organization for the diverse SNPH functions in
mitochondria, where outer membrane–associated SNPH provides
organelle attachment to the cytoskeleton (27, 29), whereas inner
membrane SNPH sustains efficient, non-leaky oxidative metabolism. Mechanistic data presented reinforce the absolute requirement of mitochondrial localization for SNPH function in tumors,
as an SNPH Δ-MLS mutant lacked the ability to affect oxidative
bioenergetics, mitochondrial trafficking to the cortical cytoskeleton, and cell proliferation.
Consistent with this view, mitochondrial SNPH emerged here
as a regulator of organelle bioenergetics, preserving the stability
and function of the complex II subunits SDHA and SDHB against
oxidative damage. Although the structural arrangement of complex II is known (34), how subunit integrity is preserved, especially
during oxidative (35) or proteotoxic (36) stress, has not been clearly delineated. We know that pharmacologic or genetic targeting of
complex II causes electron leakage (37) and increased superoxide
production (38). Here, we identified mitochondrial superoxide as
a potent stimulus for SDHA and SDHB degradation, potentially
via protein oxidation, further impairing energy production under
jci.org   Volume 127   Number 10   October 2017
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Figure 9. A mitochondrial SNPH “rheostat” for cell proliferation-motility decisions in cancer. An adequate supply of oxygen and nutrients in the tumor
microenvironment maintains high levels of SNPH in mitochondria for efficient, “non-leaky” oxidative bioenergetics and low ROS generation. These conditions support continued tumor cell proliferation while halting mitochondrial trafficking to the cortical cytoskeleton as a “regional” energy source to fuel
membrane dynamics of cell motility and invasion. Conversely, the emergence of an oxidative and hypoxic microenvironment, typical of advanced tumors,
acutely lowers SNPH levels, compromising oxidative phosphorylation complex II integrity and mitochondrial bioenergetics. The resulting increase in ROS
inhibits tumor cell proliferation, while promoting increased mitochondrial trafficking to the cortical cytoskeleton and focal adhesion kinase–dependent
(FAK-dependent) tumor cell migration and invasion. KIF5, kinesin family member 5; TRAK, trafficking kinesin-binding protein 1.

stress. How mitochondrial SNPH prevents superoxide-induced
SDHA or SDHB oxidation and degradation remains to be elucidated. One possibility is that SNPH operates in concert with other
regulators of complex II (39), including survivin (26), to preserve
subunit assembly and optimal bioenergetics, especially under
stress conditions. In fact, it is intriguing that compared with other
mitochondrial respiration complexes, complex II appears especially vulnerable to stress stimuli, including defective mitochondrial
protein folding (40–42) and oxidative damage (the present study).
Although it has long been known that tumors produce more
mitochondrial superoxide than normal tissues, a role of this
pathway in disease progression is controversial, and likely context dependent (43). Low levels of ROS may contribute to tumorigenesis via increased DNA damage and activation of oncogene
signaling (44), whereas higher generation of ROS may trigger
cytotoxicity and suppress metastasis (45). Here, the heightened
production of mitochondrial superoxide in response to SNPH
depletion triggered a dual phenotype of inhibition of tumor cell
proliferation via G2/M arrest and stimulation of cell motility by
increasing mitochondrial trafficking to the cortical cytoskeleton
(25). This is consistent with a long-held tenet that ROS mediate
cell motility (46), contributing to the acquisition of an EMT phenotype (47) and metastatic competence (21). Conversely, a role
for ROS signaling in subcellular mitochondrial trafficking and a
pathway of “regional” bioenergetics of cell motility (25) have not
been previously described.
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In terms of disease relevance, we have shown here that expression of mitochondria-localized SNPH is sufficient to suppress tumor
cell dissemination from xenograft tumors as well as in syngeneic
models of early metastatic seeding in immunocompetent animals,
defining this pathway as a conceptually novel metastasis suppressor.
Conversely, we found that SNPH becomes transcriptionally downregulated in cells that have acquired the ability to metastasize in
vivo, correlating with a cellular phenotype of heightened oxidative stress, reduced cell proliferation, and increased cell motility.
The acquisition of metastatic competence reflects a complex and
multifaceted transcriptional and posttranscriptional program (48),
including modulation of intrinsic antioxidant mechanisms (45).
How SNPH participates in this process remains to be fully elucidated, but data collected from analysis of public databases and primary patient cohorts revealed that downregulation or loss of SNPH
is a common feature of tumor progression, correlating with metastatic disease and worse outcome (29). Our data indicating that
stress conditions of the tumor microenvironment, such as hypoxia
and oxidative damage (1), acutely lower SNPH levels may explain
the silencing of this pathway in advanced disease, coinciding with
the emergence of a restrictive and unfavorable microenvironment,
typically depleted of oxygen and nutrient (1).
Based on these findings, we propose a model in which SNPH
functions as a stress-regulated mitochondrial “rheostat” for allocation of often limited resources of the microenvironment in
proliferation-motility decisions (9), or phenotype-switching (10).
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According to this model, downregulation of SNPH due to hypoxic
or oxidative stress (1) turns the rheostat toward greater cell motility
at the expense of cell proliferation (Figure 9). Fueled by increased
mitochondrial accumulation at the cortical cytoskeleton (25), the
resulting heightened cell motility may provide an “escape” mechanism for tumor cells to evade an unfavorable ecosystem and colonize alternative, distant tissue sites (49). Conversely, sustained
levels of oxygen and nutrients maintain high SNPH expression in
mitochondria. This turns the rheostat toward continued tumor cell
proliferation enabled by low ROS production and efficient oxidative metabolism, while restricting mitochondrial trafficking and
cell movements (Figure 9).
Although metastatic disease is the primary cause of death for
cancer patients, there is a paucity of therapeutic targets to interfere with the process(es) of tumor cell dissemination to distant
organs (50). In line with the renewed emphasis of mitochondria
in metastasis (19, 21, 29), molecules in the SNPH pathway may
provide fresh therapeutic opportunities to target adaptive mechanisms of cell proliferation-motility in progressive disease. As this
pathway is selectively exploited in cancer, as opposed to normal
tissues, modulators of mitochondrial trafficking may constitute a
favorable strategy and be uniquely suited to disrupt the metabolic
requirements of metastatic cells (29).

Methods

Antibodies and reagents. A custom rabbit polyclonal antibody against
human SNPH (aa 207–221) was produced by NEO Group Inc. and
purified by antigen affinity. The anti-SNPH custom antibody was
validated in knockdown cells (Supplemental Figure 1, D and E) and
in cells overexpressing SNPH cDNA (Supplemental Figure 2D) at
a 1:1,000 dilution. Antibodies to Prx3 (Santa Cruz Biotechnology
Inc., clone 4G10, catalog sc-59663, diluted 1:3,000), 2-Cys Prx-SO3
(Thermo Fisher Scientific Inc., clone 10A1, catalog LF-MA0088,
diluted 1:1,000), FLAG (Sigma-Aldrich, clone M-2, catalog F1804,
diluted 1:5,000), SDHA (Abcam, clone 2E3GC12FB2AE2, catalog
14715, diluted 1:5,000), SDHB (Abcam, clone 21A11AE7, catalog
14714, diluted 1:2,000), oxidative phosphorylation antibody cocktail (MitoSciences, Abcam catalog s110411, diluted 1:2,000), citrate
synthase (CS, clone D7V8B, catalog 14309), SOD2 (clone D3X8F,
catalog 13141), catalase (clone D4P7B, catalog 12980), Axl (clone
C89E7, catalog 8661), COX-IV (clone 4D11-B3-E8, catalog 11967),
Nrf2 (clone D1Z9C, catalog 12721), caveolin 1 (clone D46G3, catalog
3267), VDAC (catalog 4866), HIF1α (catalog 3716), β-catenin (clone
D10A8, catalog 8480), Slug (clone C19G7, catalog 9585), ZO1 (clone
D7D12, catalog 8193), claudin 1 (clone D5H1D, catalog 13255), ZEB1
(clone D80D3, catalog 3396), vimentin (clone D21H3, catalog 5741)
(Cell Signaling Technology, all diluted 1:1,000), and β-actin (Sigma-Aldrich, clone AC-15, cat#A5441, diluted 1:100,000) were used
for Western blotting. Antibodies to paxillin (Upstate Biotechnologies,
clone 5H11, Millipore catalog 05-417), β-tubulin (Sigma-Aldrich,
clone AA2, catalog T8328), Tom20 (Santa Cruz Biotechnology Inc.,
clone FL-145, catalog sc11415), and MTC02 (Abcam, clone MTC02,
catalog 79479) were used for immunofluorescence. DMNQ, FCCP,
CHX, MT (>98% TLC), and N-acetyl-cysteine (NAC, >99% HPLC)
were from Sigma-Aldrich. MitoTracker Green, phalloidin Alexa Fluor
488, CellLight Mito-RFP BacMam 2.0, and secondary antibodies for
immunofluorescence were from Molecular Probes.
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Cell culture. Human glioblastoma (LN229, U251, and U87),
prostate adenocarcinoma (LNCaP, C4-2B, DU145, and PC3), breast
epithelial (MCF10A), breast adenocarcinoma (MCF7, Hs578T, and
MDA-MB-231), lung adenocarcinoma (A549 and H1299), human
diploid fibroblasts (MRC5), prostate epithelial cells (RWPE-1), and
mouse fibroblasts (NIH 3T3) were obtained from ATCC, and maintained in culture according to the supplier’s specifications. Benign
prostate hyperplasia (BPH1) cells were a gift from Simon Hayward
(Vanderbilt University, Nashville, Tennessee, USA). A highly metastatic clone of PC3 cells colonizing the bone (PC3-ML) was a gift
from Alessandro Fatatis (Drexel University College of Medicine,
Philadelphia, Pennsylvania, USA). Primary HFFs were a gift from
Meenhard Herlyn (Wistar Institute). Yumm1.7 cells were a gift from
Marcus Bosenberg (Yale University, New Haven, Connecticut).
Hypoxic treatment was carried out using an enclosed chamber (BioSpherix) flushed with a nitrogen and CO2 gas. The O2 and CO2 concentrations in the chamber were maintained at 1% and 5%, respectively, using an oxygen and carbon dioxide controller (BioSpherix).
These conditions were maintained constant throughout the course
of the experiments.
Plasmids, mutagenesis, and transfections. TrueORF pCMV6-Entrymyc-Flag plasmids encoding the short isoform of SNPH (NM_014723,
catalog RC207749), SOD2 (catalog RC202330), and Prx3 (catalog
RC205080) were from Origene. The human ORF for the long isoform of SNPH from the Kazusa DNA Research Institute was obtained
as HaloTag(R) in pFN21A (NM_001318234.1, Promega). Short SNPH
mutants lacking the microtubule-binding domain (Δ-MTB, Δ86–159
aa), TM domain (Δ-TM, Δ425–444 aa), or MLS (Δ-MLS, Δ1–20 aa)
were generated using a Stratagene QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and confirmed by DNA
sequencing. Cells were transfected with 2 μg pcDNA plus 4 μl X-treme
gene HP (Roche) for 24 hours in complete medium, washed, and subjected to the indicated treatments.
Adenoviral vectors expressing SNPH were produced using Gateway technology (Thermo Fisher Scientific). Briefly, SNPH or LacZ
cDNA was inserted into pDONR221 vector and recombined into the
adenovirus expression vector pAd/CMV/V5-DEST. The plasmids
were digested with PacI restriction enzyme and transfected in 293A
cells for production of adenoviruses. The cells containing adenoviruses were collected at 7 days after transfection, according to the manufacturer’s instructions.
Gene silencing. Gene knockdown experiments by siRNA were carried out as described previously (20). The following sequences were
used: control, ON-TARGETplus Non-targeting siRNA pool (Dharmacon, D-001810), or human SNPH siRNA (Dharmacon, L-020417, or
Santa Cruz Biotechnology Inc., sc-41369). Tumor cells were transfected with the individual siRNA pools at 30 nM in Lipofectamine RNAiMAX (Invitrogen) at a 1:1 ratio (vol siRNA 20 μM/vol Lipofectamine
RNAiMAX). After 48 hours, the various transfected cells were validated for target protein knockdown by Western blotting and processed
for subsequent experiments. Alternatively, two independent shRNA
sequences were used for targeting the 3′ UTR of human SNPH: TRCN
0000147900 and TRCN 0000128545 (Wistar Molecular Screening
Shared Resource). An empty pLKO-based lentivirus was used as control. PC3 cells stably expressing shRNA targeting SNPH were generated by infection with lentiviral particles, followed by a 2-week selection
in the presence of puromycin at 2 μg/ml.
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Protein analysis. For Western blotting, protein lysates were prepared in Triton X-100 lysis buffer (20 mM Tris HCl, pH 7.5, 137 mM
NaCl, 1% Triton X-100, 10% glycerol) containing EDTA-free Protease
Inhibitor Cocktail (Sigma-Aldrich) and Phosphatase Inhibitor Cocktail PhosSTOP (Roche), sonicated, and precleared by centrifugation
at 14,000 g for 10 minutes at 4°C. Equal amounts of protein lysates
were separated by SDS gel electrophoresis, transferred to PVDF membranes, blocked in 5% low-fat milk diluted in TBST buffer (20 mM Tris
HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), and further incubated
with primary antibodies of various specificities diluted 1:1,000 in 5%
BSA/TBST for 18 hours at 4°C. After washing in TBST, membranes
were incubated with HRP-conjugated secondary antibodies (1:1,000–
1:5,000 dilution in 5% BSA/TBST) for 1 hour at 22°C and washed with
TBST, and protein bands were visualized by enhanced chemiluminescence. For analysis of protein stability and determination of protein
half-life, PC3 cells were incubated in the presence of 100 μg/ml of the
protein synthesis inhibitor CHX, with or without the mitochondrial
superoxide scavenger MT, and released in complete medium, and aliquots of cell lysates collected at increasing time intervals after release
(2–10 hours) were analyzed by Western blotting.
Mitochondrial isolation. Mitochondrial fractions were prepared
from PC3 cells using a mitochondrial isolation kit for cultured cells
(Fisher Scientific). Briefly, PC3 cells were homogenized by 70 strokes
using a Dounce grinder in isolation buffer A plus protease inhibitor
cocktail. Cell extracts were collected into equal volumes of isolation
buffer C with buffer A. Cell debris and nuclei were removed by centrifugation at 700 g for 10 minutes, and mitochondrial fractions were collected by centrifugation at 3,000 g for 25 minutes. For submitochondrial fractionation experiments, initial mitochondrial extracts were
further centrifuged at 12,000 g for 10 minutes in an equal volume of
isolation buffer C. The resulting samples were further processed by
sequential centrifugation in fractions containing outer membrane
(OM), inner membrane (IM), inter-membrane space (IMS), and
matrix, as described previously (42).
mRNA quantification. Absolute mRNA levels for human SNPH were
determined by qPCR. Briefly, RNA was extracted with a PureLink RNA
Mini Kit (Life Technologies) following the in-column DNA digestion
protocol. For mouse tissues, RNA was extracted from 25 mg of tissue by
homogeneization in TRI Reagent, followed by purification with a Directzol RNA Mini Kit (Zymo Research). RNA from 8 normal human tissues
was obtained from BioChain and digested with RNAse-free DNAse I
(Thermo Scientific). Five micrograms of RNA was reversed transcribed
using a combination of oligo(dT) and an SNPH-specific reverse primer
(RNAse-free HPLC purified, CTGGCGGTCACCACAGAC) for 1 hour
at 53°C using the ThermoScript RT-PCR system (Life Technologies).
One microliter of cDNA diluted 1:5 was used as template for qPCR
reactions with TaqMan Gene Expression assays. Pre-designed Taqman
assays were: mouse Snph (Mm01243855_m1), human long+short (L+S)
SNPH transcripts (Hs00920132_m1), ACTB (Hs99999903_m1), GAPDH (Hs99999905_m1), and eukaryotic 18S rRNA (4352930E).
Custom isoform-specific TaqMan gene expression assays to detect
Long human SNPH transcript (NM_001318234.1, L-SNPH), or short
human SNPH transcript (NM_014723, S-SNPH) were used (Figure
1A). Custom L-SNPH assay primers and probe were: forward, TCAGGGTTGTTGAGAGGAGTCA; reverse, CCAGTTGGCCCGTGGTT;
probe, ATAATACGGGAAGCCCC. Custom S-SNPH assay primers
and probe were: forward, AGTGGTGCGAGCCG; reverse, GGTGG3766
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GATGGGCGGTATC; probe, CAGTGGACTCAGCCCCC. A standard
synthetic gBlock containing the target amplicons for common SNPH
(S+L), short SNPH, long SNPH, actin, and GAPDH in tandem (CSLAG)
was purchased from IDT. The efficiency of amplification (Ex) of the
3 assays (long, short, and common SNPH) was determined using the
Ct slope method with 6 concentrations of CSLAG standard covering a
5-log range, and found to be identical (P > 0.05 for all comparisons). The
mean and SD were: Ex long = 82.33 ± 8.069; Ex short = 80.90 ± 2.700;
Ex common = 84.82 ± 7.179. The mean and SD for the correlation coefficients were: r2 long = 0.9975 ± 0.002500; r2 short = 0.9875 ± 0.01250; r2
common = 0.9970 ± 0.001000. All r2 values were identical (P > 0.05 for
all comparisons). Absolute copy number for each transcript was determined against a standard curve of CSLAG that was run in parallel with
the cDNA samples. For relative quantitation, the ΔΔCt method was used.
Analysis of SNPH mRNA expression in public databases. The NCBI’s
Gene Expression Omnibus (GEO) genomics data repository was interrogated for SNPH mRNA expression in primary versus metastatic cancer using the GEO Profiles Database (https://www.ncbi.nlm.nih.gov/
geoprofiles/). The “Metastatic prostate cancer” dataset GDS2545 (51,
52) containing 65 primary prostate and 15 metastases to regional and
distal lymph nodes was downloaded. The study contained one probeset for SNPH (4117_at, GPL8300: [HG_U95Av2] Affymetrix Human
Genome U95 Version 2 Array). The “Human epidermal growth factor
receptor 2–positive breast cancer brain metastases” dataset GDS5306
(53) containing 19 HER+ breast primary non-metastatic and 19 brain
metastases was downloaded. The study contained 5 probesets for
SNPH: each probe was searched in the GPL1352: [U133_X3P] Affymetrix Human X3P Array and matched to gene bank ID, and the sequence
was downloaded from the NCBI nucleotide collection and blasted
against the Human Genomic Plus Transcript (Human G+T). Four
probes (Hs.323833.1.S1_3p_a_at, Hs.323833.1.S1_3p_at, 215917_3p_at,
and Hs.323833.1.S1_3p_x_at) were primarily covering a neighbor gene,
RAD21L1 (NM_001136566.2 at 61% coverage), with a lower coverage
for SNPH isoforms (38% for either isoform). These 4 probes were discarded from the analyses. Only one probe (ID: g7662081_3p_at) was a
bona fide probe for SNPH (both isoforms were detected; 100% coverage for NM_001318234.1 and 89% coverage for NM_014723.3). Based
on this probe, primary versus metastatic tumors were compared with a
2-tailed unpaired Student’s t test using GraphPad Prism 6.0 software.
For the Cancer Cell Line Encyclopedia (CCLE) (54), mRNA
expression for SNPH was accessed through the cBioPortal for Cancer Genomics (http://www.cbioportal.org/) (55, 56) and downloaded. Individual cancer cell lines were grouped by primary tissue of
origin according to the CCLE classification and plotted with GraphPad Prism 6.0 software. The TCGA tumor expression data for SNPH
mRNA (RNA-seq values) were downloaded from the cBioPortal and
plotted with GraphPad Prism 6.0 software.
For the SNPH versus VHL status analysis, the Kidney Renal Clear
Cell Carcinoma study (The Cancer Genome Atlas [TCGA; https://cancergenome.nih.gov/], Provisional) was downloaded through the cBioPortal (55, 56), and the levels of SNPH mRNA were plotted against
the copy number variation/mutation status of VHL. Outliers were
tested with Grubbs test and removed from the dataset, and the multiple groups were tested with 1-way ANOVA and Bonferroni’s post-test
for pairwise comparisons. A correlation between SNPH mRNA levels
and linear copy number alteration (CNA) for VHL were was examined
using Spearman’s test using GraphPad Prism 6.0 software.
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Immunofluorescence. Tumor cells were fixed in formalin/PBS (4%
final concentration) for 15 minutes at 22°C, permeabilized in 0.1% Triton X-100/PBS for 5 minutes, washed, and incubated in 5% normal
goat serum (NGS, Vector Laboratories) diluted in 0.3 M glycine/PBS
for 60 minutes. Primary antibodies against Tom20 (diluted 1:300),
β-tubulin (diluted 1:200), SNPH (diluted 1:500), and MTC02 (diluted 1:500) were added in 5% NGS/0.3 M glycine/PBS and incubated
for 18 hours at 4°C. After 3 washes in PBS, secondary antibodies conjugated to Alexa Fluor 488, TRITC, or Alexa Fluor 633 were diluted
1:500 in 5% NGS/0.3 M glycine/PBS and added to cells for 1 hour at
22°C. Where indicated, F-actin was stained with phalloidin Alexa Fluor 488 (1:200 dilution) for 30 minutes at 22°C. Slides were washed
and mounted in DAPI-containing ProLong Gold mounting medium
(Invitrogen). At least 7 random fields were analyzed by fluorescence
microscopy in a Nikon i80 microscope.
Cortical mitochondria and total mitochondrial mass quantification.
Mitochondria/F-actin composite images were analyzed in ImageJ
(NIH), as described previously (25). The F-actin channel was used
to manually label the cell boundary, and a belt extending from the
boundary toward the inside of the cell was marked as “cortical mask”
(see Figure 4B). This cortical mask was subsequently applied to the
mitochondrial channel to measure intensity at the cortical region,
which was normalized to total mitochondrial intensity per cell and cell
area. For quantification of total mitochondrial mass, composite images were analyzed in ImageJ. The cell border was manually traced on
the F-actin channel, and this “cell mask” was subsequently applied to
the mitochondria channel to measure the total mitochondria signal
per cell. Maximum intensity was monitored to ensure no pixel saturation (e.g., maximum intensity <256 for 8-bit images). Mitochondrial
mass was normalized to total cell area. A minimum of 30 cells was
analyzed in each independent experiment to obtain mean values.
Mitochondrial ROS quantification in live cells. Mitochondrial superoxide production was analyzed as described previously (25). Briefly,
1.5 × 104 cells were grown on high-optical-quality 8-well μ-slides (Ibidi) and stained with MitoSOX Red mitochondrial superoxide indicator
(Life Technologies, 5 μM, 10 minutes) in complete medium, followed
by washes in warm medium. Stained cells were imaged with a 40×
objective on a Nikon TE300 inverted time-lapse microscope equipped
with a video system containing an Evolution QEi camera and a timelapse video cassette recorder. The atmosphere was equilibrated to
37°C and 5% CO2 in an incubation chamber. Phase and red fluorescence (TRITC filter cube, excitation wavelength 532–554 nm, and
emission wavelength 570–613 nm) images were captured. For quantification, files were imported into ImageJ, and masks were manually
created around the periphery of the cell based on the phase image and
subsequently applied to the TRITC channel to measure intensity. A
minimum of 100 cells was analyzed in each independent experiment
to obtain mean values.
Analysis of bioenergetics. Cells were analyzed for ATP generation
(BioChain catalog Z5030041) or OCR (Enzo Life Sciences catalog
ENZ-51045-1), according to the manufacturer’s specifications. In
some experiments, the culture medium was exchanged with dialyzed
FBS containing growth medium and incubated for 2 hours, followed by
analysis of lactate production (Abcam, catalog ab65331). For glucose
consumption, cells were grown for 24 hours at 37°C, and aliquots of
the culture supernatant were collected and processed using a glucose
assay kit (eEnzyme).
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Mitochondrial respiration complex activity. Extracts from PC3 cells
stably transduced with pLKO or SNPH-directed shRNA were analyzed for changes in oxidative phosphorylation complex activity using
Abcam reagents (for complex I, ab109721; for complex II, ab109908).
Twenty micrograms of cell lysates was assayed in parallel for citrate
synthase (CS) activity (ScienCell Research Laboratories). Aliquots
of lysates with comparable CS activity were applied for quantification
of mitochondrial oxidative phosphorylation complex activity. Relative complex activities were calculated by determining the change in
absorbance over time in the linear range of the measurements.
Cell motility analysis. 2D tumor cell motility experiments were
carried out as described previously (25). Briefly, 1 × 104 cells under
the various conditions tested were seeded in 4-well Ph+ chambers
(Ibidi) in complete medium and allowed to attach overnight. Videomicroscopy was performed over 10 hours, with a time-lapse interval of 10 minutes. Stacks were imported into ImageJ for analysis.
Images were aligned according to subpixel intensity registration with
the StackReg plugin for ImageJ. At least 30 cells were tracked using
the Manual Tracking plugin for ImageJ, and the tracking data from
4 independent time-lapse experiments were pooled and exported
into Chemotaxis and Migration Tool v2.0 (Ibidi) for graphing and
calculation of mean and SD of speed, accumulated distance, and
Euclidean distance of movement. For cell migration using a wound
closure assay, a monolayer of PC3 cells was incubated at 1% O2 for
24 hours, wounded using a 10-μl pipette tip, immediately returned
to the hypoxia chamber, and incubated for an additional 20 hours in
1% O2. Cells were imaged by phase-contrast microscopy,and images were imported into FIJI software (http://fiji.sc/) and processed to
measure the area within the wound. The percentage of wound closure was calculated based on the maximum initial area for each well.
Cell proliferation. For direct cell counting experiments, tumor cells
were plated in triplicate on 6-MW plates (4 × 104 cells/well) and counted
at increasing time intervals at 37°C. In parallel, cell viability was measured by Trypan blue exclusion. Where indicated, ROS scavengers, MT
(50 μM), or NAC (10 μM), alone or in combination, were added to the
medium, and fresh medium containing drugs was added every 2 days.
For colony formation, 200 cells were plated in triplicate onto 6-MW
plates and allowed to grow for 10–14 days, with fresh medium added
every 2–3 days. Colonies were stained with 0.5% w/v crystal violet/methanol for 30 minutes at 22°C and quantified by ImageJ. Cell proliferation
experiments were done by labeling cells in 1:1,000 dilution BrdU (Amersham Pharmacia Biotech) in culture medium for 1 hour and analysis by
multiparametric flow cytometry with quantitation of BrdU+ cells. Cell
cycle analysis was carried out in ethanol-fixed cells, stained for 10 minutes with 2.5 μl/ml propidium iodide in the presence of ribonuclease A.
Twenty thousand events were acquired on a FACSCalibur flow cytometer and quantified using CellQuest Pro software (Becton Dickinson).
Animal studies. Groups of 6- to 8-week-old male NOD SCID γ
(NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) immunocompromised mice
(Jackson Laboratory) (5 mice per group) were injected s.c. with PC3
cells stably transfected with pLKO or two independent SNPH-directed
shRNA sequences (clones 0 and 5), and superficial tumor growth (2
tumors/mouse) was quantified with a caliper over a 2-week interval.
At the end of the experiment, animals bearing PC3-pLKO (puromycin-resistant) tumors were euthanized, and the liver and lungs were
dissected and washed in PBS. Metastatic nodules were excised and cut
into 1-mm sections, washed in PBS, and plated in RPMI 1640 medijci.org   Volume 127   Number 10   October 2017
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um containing puromycin. Tumor cells were allowed to attach to the
plate overnight, and the next day any residual tissue fragments were
removed. Four animals were used to generate 4 independent cell lines
from liver and lung metastatic sites. Parental PC3-pLKO cells were
used as control for these experiments.
For a syngeneic model of metastasis in vivo, Yale University
Mouse Melanoma 1.7 (Yumm1.7) 1.7 cells derived from a genetically engineered mouse model of invasive melanoma with the genotype BrafV600E; Cdkn2a–/–;Pten–/– were used (31). Yumm1.7 cells stably
expressing mCherry were described previously (32). Cells were transiently transfected with empty pCMV6 vector, or cDNAs encoding FL
short SNPH or ΔMLS SNPH mutant, and selected with G418 at 400
μg/ml for 15 days. Stably transfected cells (2.5 × 105) were injected into
the flanks of syngeneic 8-week-old male C57BL/6NCr (NCI Inbred
mice, Charles River strain code 556). One to 3 weeks later, tumor
cells disseminated to lungs were identified and quantitated based on
expression of the mCherry transgene by IHC (see below).
IHC. Lungs were fixed in neutral formalin (Fisher Scientific, SF934) for 36 hours, transferred to 70% ethanol for 3 days, and then paraffin embedded. Five-micrometer sections were stained with a rabbit
anti-mCherry polyclonal antibody (Novus, NBP2-25157) as follows.
Slides were warmed at 50°C for 30 minutes; deparaffinized in xylene
for 20 minutes, then xylene/ethanol 1:1 for 5 minutes; and rehydrated in alcohol series (100%, 95%, 90%, 70%, 50%, 30% ethanol and
dH2O, 5 minutes each). Antigen retrieval was done in citrate-based solution (Vector Laboratories, H-3300) at pH 6.0 in a pressure cooker for
5 minutes, followed by cooling to room temperature. Next, slides were
washed once in PBS for 5 minutes and incubated in 3% hydrogen peroxide for 20 minutes. Slides were then washed 3 times with PBS (5 minutes
each) and blocked in 10% normal goat serum/PBS for 1 hour at room
temperature. Primary antibody was diluted 1:500 in 10% normal goat
serum/PBS and incubated in a humidified chamber overnight. The next
day, slides were washed 3 times with PBS for 5 minutes each, incubated
with anti-rabbit HRP-labeled polymer (Dako, K4002) at room temperature for 30 minutes, and washed 3 times with PBS for 5 minutes each.
Slides were developed with a DAB+ substrate chromogen system (Dako,
K3467) for 30 minutes, rinsed in dH2O, and stained with Mayer’s hematoxylin solution (Sigma-Aldrich, MHS16) for 10 seconds. Slides were
dehydrated in dH2O, 30%, 50%, 70%, 90%, 95%, and 100% ethanol
(5 minutes each); immersed in xylene for 15 minutes; and mounted with
Permount mounting medium (Fisher Scientific, SP15-100).
Quantification of disseminated tumor cells to the lungs. Five lungs
per group were stained for mCherry as described above and scanned
for the presence of mCherry+ cells in a Nikon i80 upright microscope.
Each mCherry+ cell was photographed at 40× magnification and
manually counted using ImageJ software. For each animal, the average number of mCherry+ cells per lung was calculated and presented.
ANOVA with Bonferroni’s post-test was used to compare the means
between the groups and derived pairwise comparison P values.
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